What topics does this cannabis study cover?

This study covers research on: THC.

Where was this research published?

Published in The International journal on drug policy on April 14, 2026.

THC

Drug seizures don't stop markets—study reveals enforcement limitations

Seizure-to-market ratios and the resilience of the drug markets in France (2010-2023).

The International journal on drug policy • April 14, 2026 • Moderately Relevant

🤖

AI Summary

This study challenges a core assumption of drug law enforcement: that seizing large quantities of drugs effectively disrupts markets. Researchers compared estimated cannabis consumption in France (approximately 400 tonnes annually) with official seizure volumes from 2010-2023, calculating what percentage of the drug market was actually intercepted. For cannabis, seizures captured only 20-30% of estimated consumption, while for heroin, the ratio was 13-16%. Interestingly, despite these substantial seizure volumes, the market showed remarkable resilience—retail prices remained stable or actually declined during this period.

The most striking finding was that market indicators told a consistent story: prices didn't spike, product purity increased, and availability remained strong, all pointing to the conclusion that seizures had limited impact on drug availability. For cocaine, France's unique role as a European transit point created unusually high seizure ratios (46-122% in 2017), but even these extraordinary interception rates didn't destabilize the broader market. The research highlights a critical gap in drug policy evaluation—current law enforcement metrics focus on seizure volumes, but these numbers may not reflect actual market disruption or reduced harm.

These findings have important implications for cannabis policy and drug law enforcement strategy. If seizures alone cannot meaningfully reduce availability or increase prices, then current supply-side enforcement approaches may need fundamental reassessment. The study suggests that more comprehensive policy indicators beyond seizure statistics are needed to properly evaluate whether drug enforcement actually achieves its stated goals of reducing consumption, crime, and harms.

📄 Original Abstract

Drug seizures are widely used as indicators of law enforcement performance, yet their ability to disrupt drug markets remains unclear. Recent evidence highlights the lack of rigorous empirical research assessing whether seizures reduce drug availability, crime, or harms. This study compares estimated quantities consumed in France with official seizure volumes to evaluate the relative scale and policy relevance of drug seizures. We used a demand-side, bottom-up approach to estimate consumption volumes for cannabis, cocaine, heroin, MDMA/ecstasy, and amphetamines for 2010, 2017, and 2023. These estimates were derived from representative population surveys and consumption indicators. Seizure volumes were drawn from national statistics. Seizure-to-market ratios were computed for each substance and year. In 2023, estimated consumption reached approximately 400 tonnes of cannabis, 47 tonnes of cocaine, 8 tonnes of heroin, 65 million MDMA/ecstasy tablets, and 5.6 tonnes of amphetamines. Seizure-to-market ratios show stable proportions for cannabis (20-30%) and heroin (13-16%), low ratios for MDMA/ecstasy (3-20%), and unusually high ratios for cocaine in 2017 (46-122%), reflecting France's role as an interception point for Europe-bound trafficking. Despite these seizure volumes, retail prices remained stable or declined, while purity and inflation were rising over the same period. The convergence of our estimated seizure ratios with contextual market indicators (stable or falling prices, increasing purity, and inflation) suggests that drug markets remained resilient and that seizures had limited impact on availability. These findings underscore the need for more comprehensive indicators to evaluate supply-side drug policies.